跳至主要内容
临床试验/ISRCTN14603929
ISRCTN14603929进行中(未招募)未知

Super Rehab”: Can we achieve coronary artery disease regression? (a feasibility study)

Royal United Hospital Bath NHS Trust0 个研究点目标入组 43 人开始时间: 2022年1月26日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
43

研究概览

简要总结

2023 Protocol article in https://doi.org/10.1136/bmjopen-2023-080735 (added 13/12/2023)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Current inclusion criteria as of 13/10/2022:
  • 1. 18 - 75 years of age
  • 2. Confirmed coronary artery disease on CT coronary angiography, with at least one coronary artery with plaque affecting =25% of the lumen, and evidence of coronary inflammation (defined by an abnormal fat attenuation index (FAI) of > -70.1HU or with FAI score [relative to age and sex matched patients] = 75th percentile in the left anterior coronary or right coronary artery or with FAI score = 90th percentile in the circumflex artery)
  • 3. Have Metabolic Syndrome, defined as meeting any 3 of the following within 6 months of their cardiac CT: high abdominal waist circumference (=94cm males, =80cm females), hypertension (=130/85mmHg or on treatment), raised fasting glucose or HbA1c (glucose =5.6mmol/L, HbA1c =42mmol/L or on diabetic treatment), low HDL (=1mmol/L males, <1.3mmol/L females), and high triglycerides (>1.7mmol/L)
  • 4. Able and willing to safely comply with all study procedures
  • 5. Able to provide written informed consent for participation whilst acknowledging their freedom to withdraw at any point during the study
  • Previous inclusion criteria:
  • 1. 18 - 75 years of age
  • 2. Confirmed coronary artery disease on CT coronary angiography, with at least one coronary artery with plaque affecting =25% of the lumen, and evidence of coronary inflammation, as defined by an abnormal fat attenuation index of >-70.1HU
  • 3. Meet streamlined criteria for identification of metabolic syndrome, including a high body mass index of >28 kg/m2, and abnormal blood glucose control (defined as HbA1c >42 mmol/mol / >6%)
  • 4. Able and willing to safely comply with all study procedures
  • 5. Able to provide written informed consent for participation whilst acknowledging their freedom to withdraw at any point during the study

排除标准

  • 1. Prognostic coronary artery disease, defined as left main stem >50% stenosis, flow-limiting disease in the proximal left anterior descending artery, or at least moderate disease in =3 major epicardial vessels
  • 2. Unstable angina
  • 3. New York Heart Association class III/IV heart failure or severe left ventricular impairment
  • 4. Significant cardiomyopathy (as assessed by a cardiologist, e.g. hypertrophic cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy)
  • 5. Severe heart valve disease
  • 6. Severe hypertension (BP >180/120 mmHg) despite optimising anti-hypertensive therapy
  • 7. Uncontrolled cardiac arrhythmia or higher degree heart block
  • 8. History of aortic dissection
  • 9. Recent acute pulmonary embolus, deep vein thrombosis, stroke or transient ischaemic attack
  • 10. Severe autonomic or peripheral neuropathy
  • 11. Acute systemic illness of fever
  • 12. Significant acute or chronic renal failure
  • 13. Pulmonary fibrosis or interstitial lung disease
  • 14. Physically unable to participate in high-intensity exercise
  • 15. A history of prior heart attack or coronary re-vascularisation (entitled to existing cardiac rehabilitation)
  • 16. Severe coronary calcification precluding assessment of the coronary lumen on CT coronary angiography
  • 17. A clinically significant ECG abnormality at the screening visit, which in the opinion of the investigators exposes the subject to risk by enrolling in the trial
  • 18. Pregnant or breastfeeding
  • 19. Participation in another intervention-based research study
  • 20. Inability to fully understand the instructions provided during the study

研究者

发起方
Royal United Hospital Bath NHS Trust

相似试验